Please try another search
For the nine months ended 30 September 2019, Melinta Therapeutics Inc revenues decreased 25% to $45.9M. Net loss increased from $113.1M to $276.1M. Revenues reflect License decrease of 96% to $900K, Contract research decrease of 59% to $3.6M. Higher net loss reflects Change in fair value of warrant and conv decrease of 66% to $10.4M (income), Reversal of loss contract decrease from $5.3M (income) to $0K.
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Revenue | 15.87 | 15.96 | 14.08 | 35.49 |
Gross Profit | 7.66 | 7.32 | 6.72 | 26.5 |
Operating Income | -210.48 | -27.14 | -24.93 | -38.45 |
Net Income | -213.38 | -36.18 | -26.53 | -44.12 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Assets | 228.49 | 440.37 | 470.45 | 441.59 |
Total Liabilities | 289.02 | 298.7 | 293.93 | 251.53 |
Total Equity | -60.53 | 141.67 | 176.52 | 190.06 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -89.82 | -63 | -37.32 | -171.54 |
Cash From Investing Activities | -1.22 | -1.22 | -1.22 | -170.07 |
Cash From Financing Activities | 72.75 | 72.75 | 73.64 | 295.04 |
Net Change in Cash | -18.29 | 8.54 | 35.09 | -46.58 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review